Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 44 articles: HTML format

Single Articles

June 2025
1. WANG JH, Sherry AD, Bazyar S, Sutera P, et al
   Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.
   J Clin Oncol. 2025;43:2059-2068.
   PubMed     Abstract available
   
   
   
2. STEIN MN, Vinceneux A, Robbrecht D, Doger B, et al
   Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study.
   J Clin Oncol. 2025 Jun 1:101200JCO2500678. doi: 10.1200/JCO-25-00678.
   PubMed     Abstract available
   
   
   May 2025
3. HASSANZADEH C, Kuban D, Pasyar S, Bassett R, et al
   Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial.
   J Clin Oncol. 2025 May 14:JCO2402057. doi: 10.1200/JCO-24-02057.
   PubMed     Abstract available
   
   
   
4. GARJE R, Riaz IB, Naqvi SAA, Rumble RB, et al
   Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.
   J Clin Oncol. 2025 May 2:JCO2500007. doi: 10.1200/JCO-25-00007.
   PubMed     Abstract available
   
   
   April 2025
5. KUNZ N, Kemper C
   Complementing Anticancer Therapy: Antibody-Drug Conjugates Targeting CD46 as Prostate Cancer Treatment.
   J Clin Oncol. 2025 Apr 22:JCO2500457. doi: 10.1200/JCO-25-00457.
   PubMed    
   
   
   
6. ARMSTRONG AJ, Liu VYT, Selvaraju RR, Chen E, et al
   Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.
   J Clin Oncol. 2025 Apr 16:JCO2400365. doi: 10.1200/JCO.24.00365.
   PubMed     Abstract available
   
   
   March 2025
7. AGGARWAL RR, Vuky J, VanderWeele D, Rettig M, et al
   Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer.
   J Clin Oncol. 2025 Mar 26:JCO2401989. doi: 10.1200/JCO-24-01989.
   PubMed     Abstract available
   
   
   
8. SLOVIN SF
   Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why?
   J Clin Oncol. 2025 Mar 13:JCO2402402. doi: 10.1200/JCO-24-02402.
   PubMed    
   
   
   
9. PETRYLAK DP, Ratta R, Matsubara N, Korbenfeld E, et al
   Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.
   J Clin Oncol. 2025 Mar 5:JCO2401283. doi: 10.1200/JCO-24-01283.
   PubMed     Abstract available
   
   
   January 2025
10. SAAD F, Vjaters E, Testa I, Haresh KP, et al
    Reply to: Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.
    J Clin Oncol. 2025 Jan 17:JCO2402742. doi: 10.1200/JCO-24-02742.
    PubMed    
    
    
    
11. MITTAL A, Linford G, Gyawali B
    Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.
    J Clin Oncol. 2025 Jan 17:JCO2402314. doi: 10.1200/JCO-24-02314.
    PubMed    
    
    
    
12. YU EY, Rumble RB, Agarwal N, Cheng HH, et al
    Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline.
    J Clin Oncol. 2025 Jan 9:JCO2402608. doi: 10.1200/JCO-24-02608.
    PubMed     Abstract available
    
    
    December 2024
13. DIZMAN N, Necchi A
    Promises and Challenges of Dietary Intervention in Patients With Prostate Cancer: Lessons Learned From the CAPFISH-3 Trial.
    J Clin Oncol. 2024 Dec 13:JCO2402444. doi: 10.1200/JCO-24-02444.
    PubMed    
    
    
    
14. ARONSON WJ, Grogan T, Liang P, Jardack P, et al
    High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial.
    J Clin Oncol. 2024 Dec 13:JCO2400608. doi: 10.1200/JCO.24.00608.
    PubMed     Abstract available
    
    
    October 2024
15. BROOKS JD
    Stockholm3 in a Multiethnic Cohort: Optimizing Prostate Cancer Screening to Reduce Harm and Improve Equity.
    J Clin Oncol. 2024 Oct 3:JCO2400941. doi: 10.1200/JCO.24.00941.
    PubMed    
    
    
    September 2024
16. MONTORSI F, Longoni M, Briganti A, Gandaglia G, et al
    Improving Assessment of Radiorecurrent Prostate Cancer: Implications for Salvage Reirradiation.
    J Clin Oncol. 2024 Sep 17:JCO2401067. doi: 10.1200/JCO.24.01067.
    PubMed    
    
    
    
17. SAAD F, Vjaters E, Shore N, Olmos D, et al
    Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
    J Clin Oncol. 2024 Sep 16:JCO2401798. doi: 10.1200/JCO-24-01798.
    PubMed     Abstract available
    
    
    
18. TOMBAL B, Giannarini G
    Systemic Treatment for Biochemical Recurrence of Localized Prostate Cancer: Do Not EMBARK on When, If the Answer Is How.
    J Clin Oncol. 2024 Sep 6:JCO2401134. doi: 10.1200/JCO.24.01134.
    PubMed    
    
    
    July 2024
19. VIGNESWARAN HT, Eklund M, Discacciati A, Nordstrom T, et al
    Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial.
    J Clin Oncol. 2024 Jul 22:JCO2400152. doi: 10.1200/JCO.24.00152.
    PubMed     Abstract available
    
    
    June 2024
20. GARCIA JA, Spratt DE
    Is It Premature to Accept Radiographic Progression-Free Survival as a Surrogate End Point in Metastatic Hormone-Sensitive Prostate Cancer?
    J Clin Oncol. 2024 Jun 14:JCO2400210. doi: 10.1200/JCO.24.00210.
    PubMed    
    
    
    May 2024
21. LEE WR, Dignam JJ, Amin MB, Bruner DW, et al
    Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
    J Clin Oncol. 2024 May 17:JCO2302445. doi: 10.1200/JCO.23.02445.
    PubMed     Abstract available
    
    
    
22. EINSTEIN DJ, Regan MM, Stevens JS, McDermott DF, et al
    Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.
    J Clin Oncol. 2024 May 16:JCO2400279. doi: 10.1200/JCO.24.00279.
    PubMed     Abstract available
    
    
    
23. SPRATT DE
    Prostate-Specific Antigen Nadir Postradiotherapy in Localized Prostate Cancer: Is It Prognostic or Predictive?
    J Clin Oncol. 2024 May 14:JCO2302689. doi: 10.1200/JCO.23.02689.
    PubMed    
    
    
    
24. SAYAN M, Chen MH, Loffredo M, McMahon E, et al
    Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis.
    J Clin Oncol. 2024 May 1:JCO2302394. doi: 10.1200/JCO.23.02394.
    PubMed     Abstract available
    
    
    April 2024
25. EKANGER C, Helle SI, Reisaeter L, Hysing LB, et al
    Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up.
    J Clin Oncol. 2024 Apr 23:JCO2301391. doi: 10.1200/JCO.23.01391.
    PubMed     Abstract available
    
    
    
26. 
    Erratum: Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.
    J Clin Oncol. 2024 Apr 16:JCO2400454. doi: 10.1200/JCO.24.00454.
    PubMed    
    
    
    March 2024
27. YU JB, DeStephano DM, Jeffers B, Horowitz DP, et al
    Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
    J Clin Oncol. 2024 Mar 20:JCO2301604. doi: 10.1200/JCO.23.01604.
    PubMed     Abstract available
    
    
    
28. MADAN RA, Yu EY, Posadas EM, Lee RJ, et al
    Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care.
    J Clin Oncol. 2024 Mar 15:JCO2302727. doi: 10.1200/JCO.23.02727.
    PubMed     Abstract available
    
    
    
29. FALLAH J, Xu J, Weinstock C, Gao X, et al
    Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
    J Clin Oncol. 2024 Mar 14:JCO2302105. doi: 10.1200/JCO.23.02105.
    PubMed     Abstract available
    
    
    
30. KWAK L, Ravi P, Armstrong JG, Beckendorf V, et al
    Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.
    J Clin Oncol. 2024 Mar 12:JCO2300762. doi: 10.1200/JCO.23.00762.
    PubMed     Abstract available
    
    
    
31. HEISS BL, Chang E, Gao X, Truong T, et al
    US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2024 Mar 7:JCO2302182. doi: 10.1200/JCO.23.02182.
    PubMed     Abstract available
    
    
    January 2024
32. AGGARWAL R, Heller G, Hillman DW, Xiao H, et al
    PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
    J Clin Oncol. 2024 Jan 23:JCO2301157. doi: 10.1200/JCO.23.01157.
    PubMed     Abstract available
    
    
    
33. CHILDS DS, Orme JJ, Ravi P
    Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?
    J Clin Oncol. 2024 Jan 23:JCO2302410. doi: 10.1200/JCO.23.02410.
    PubMed    
    
    
    
34. HALABI S, Roy A, Rydzewska L, Guo S, et al
    Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2024 Jan 5:JCO2301535. doi: 10.1200/JCO.23.01535.
    PubMed     Abstract available
    
    
    
35. DENMEADE SR
    Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer.
    J Clin Oncol. 2024 Jan 5:JCO2302310. doi: 10.1200/JCO.23.02310.
    PubMed    
    
    
    December 2023
36. FALLAH J, Xu J, Weinstock C, Brave MH, et al
    FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Dec 21:JCO2301868. doi: 10.1200/JCO.23.01868.
    PubMed     Abstract available
    
    
    November 2023
37. MATEO J, de Bono JS, Fizazi K, Saad F, et al
    Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300339. doi: 10.1200/JCO.23.00339.
    PubMed     Abstract available
    
    
    
38. ROY S, Romero T, Michalski JM, Feng FY, et al
    Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.
    J Clin Oncol. 2023;41:5005-5014.
    PubMed     Abstract available
    
    
    
39. GARJE R, Rumble RB, Parikh RA
    Systemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2023 Nov 6:JCO2302128. doi: 10.1200/JCO.23.02128.
    PubMed     Abstract available
    
    
    
40. TAGAWA ST, Thomas C, Sartor AO, Sun M, et al
    Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of (225)Ac-J591.
    J Clin Oncol. 2023 Nov 3:JCO2300573. doi: 10.1200/JCO.23.00573.
    PubMed     Abstract available
    
    
    October 2023
41. GONG J, Kim DM, De Hoedt AM, Bhowmick N, et al
    Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?
    J Clin Oncol. 2023 Oct 27:JCO2300949. doi: 10.1200/JCO.23.00949.
    PubMed     Abstract available
    
    
    
42. MADAN RA, Karzai F, VanderWeele DJ, Cheng HH, et al
    Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits.
    J Clin Oncol. 2023 Oct 17:JCO2301502. doi: 10.1200/JCO.23.01502.
    PubMed    
    
    
    September 2023
43. FRANCOLINI G, Gaetano Allegra A, Detti B, Di Cataldo V, et al
    Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).
    J Clin Oncol. 2023 Sep 21:JCO2300985. doi: 10.1200/JCO.23.00985.
    PubMed     Abstract available
    
    
    
44. STAR J, Bandi P, Siegel RL, Han X, et al
    Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic.
    J Clin Oncol. 2023;41:4352-4359.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.